FibroBiologics (NASDAQ:FBLG) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a research report released on Friday morning,Benzinga reports. D. Boral Capital currently has a $16.00 price objective on the stock.

Several other analysts also recently weighed in on FBLG. Maxim Group started coverage on FibroBiologics in a research note on Tuesday, September 24th. They set a “buy” rating and a $12.00 target price on the stock. EF Hutton Acquisition Co. I raised shares of FibroBiologics to a “strong-buy” rating in a report on Wednesday, September 4th. Rodman & Renshaw assumed coverage on shares of FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of FibroBiologics in a research note on Wednesday, November 13th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Stock Performance

NASDAQ FBLG opened at $2.36 on Friday. The company has a 50-day moving average price of $2.66 and a two-hundred day moving average price of $3.29. FibroBiologics has a 52 week low of $1.08 and a 52 week high of $55.00.

Institutional Trading of FibroBiologics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its position in FibroBiologics by 5.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock worth $215,000 after buying an additional 3,451 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of FibroBiologics in the 3rd quarter worth $32,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of FibroBiologics during the second quarter worth $51,000. Jane Street Group LLC purchased a new stake in shares of FibroBiologics during the third quarter valued at $37,000. Finally, Cahaba Wealth Management Inc. purchased a new position in FibroBiologics in the 2nd quarter worth about $73,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.